Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. reports clinical-stage biopharmaceutical developments focused on targeted, non-systemic therapies for gastrointestinal diseases. Recurring news includes updates on latiglutenase, an oral biotherapeutic composed of gluten-specific recombinant proteases for celiac disease, as well as scientific publications, conference abstracts, and diagnostic research related to serologic and mucosal measures in celiac disease.
Company updates also cover investor conference participation, clinical development strategy, material agreements, shareholder voting matters, capital-structure disclosures, governance items, operating results, and clinical or regulatory disclosures tied to its GI disease pipeline.
Entero Therapeutics, formerly First Wave BioPharma, has rebranded to reflect its focus on gastrointestinal (GI) diseases. The company, now trading under the ticker 'ENTO' effective May 17, 2024, is advancing toward a Phase 3 trial for latiglutenase. This lead asset has shown promise in Phase 2 trials for treating celiac disease, a condition with no current approved treatments. The rebranding follows the acquisition of ImmunogenX and aims to align with Entero's mission to address unmet needs in GI health. The Phase 3 trial is expected to commence in early 2025. Entero will also participate in Celiac Awareness Month by partnering with Celiac Journey for a digital display at the Nasdaq Tower in Times Square.
First Wave BioPharma, Inc. is set to raise approximately $1.1 million in gross proceeds through a registered direct offering priced at-the-market. The Company entered into a securities purchase agreement with an institutional investor for the sale of 366,000 shares of common stock at $2.95 per share. Additionally, warrants to purchase up to 732,000 shares will be issued to the investor at $2.70 per share. The offering, facilitated by Roth Capital Partners, aims to bolster the Company's working capital and general corporate purposes.
First Wave BioPharma, Inc. (NASDAQ: FWBI) partners with Celiac Journey for Celiac Disease Awareness Month to host an event at Nasdaq Tower in Times Square. The event aims to raise awareness about celiac disease, advocate for research, and support the 3.3 million individuals in the U.S. impacted by the condition. The company will showcase a digital display and host a photo event featuring celiac disease advocates and experts. CEO James Sapirstein highlights the lack of treatment options for celiac disease and the company's dedication to developing innovative therapies for GI diseases. Co-founder of Celiac Journey, Jax Bari, emphasizes the challenges faced by individuals with celiac disease and the need for improved research funding and alternative treatments. Co-founder Jon Bari stresses the importance of labeling gluten grains for a better quality of life and safety for celiacs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.